HEALTHSTORY 1103· JUNE 26, 2026

One Patient Has Been Granted Exclusive Access to Eli Lilly's Obesity Drug Retatrutide Through FDA Compassionate Use

The Food and Drug Administration and Eli Lilly have permitted a single individual to receive retatrutide — Lilly's highly anticipated obesity drug candidate — through the FDA's compassionate use program, according to a scoop by STAT News…

NDNewsDialy Desk2 MIN READLLY

SOURCE

statnews.com

← PREVIOUS STORY 1102SpaceX Stock Slides 14%, on Pace for Third Straight Day of Losses as Post-IPO Rally Fades NEXT STORY 1104 →Airwallex Raises $320 Million at $11 Billion Valuation to Build Financial Infrastructure for AI Agents

Keep reading

More from the desk.

02HEALTH

Novartis shares drop 11% on drug failure as biosimilar gap threatens $200 billion in savings

A failed clinical trial wiped nearly $30 billion from Novartis's market value this week after shares fell 11% in a single session, erasing all the gains the stock had made since the start of the year. The drug that failed, del-desiran, was…

health2 MIN

10HEALTH

EU legal adviser hands pharma a win on wastewater costs

Pharmaceutical and cosmetics companies across Europe may be off the hook for the largest share of a continent-wide water cleanup effort, after a legal adviser to the EU's top court recommended striki

health2 MIN

11HEALTH

FDA clears first drug to target muscle loss in spinal muscular atrophy

Federal regulators approved a drug on Friday for spinal muscular atrophy, a rare neurological condition where the nerve cells that signal muscles to move gradually deteriorate. The drug, Isembyld, is the first approved therapy to directly…

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk